(P054) Carbon Ion Therapy for Chinese Patients With Prostate Cancer: Primary Reports

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

This is the first report about a Chinese population with prostate cancer treated with carbon ion therapy. Our primary data showed that carbon ion therapy was well tolerated, and the immediate effect was encouraging. Long-term follow-up is needed for the analysis of final treatment responses and toxicities.

Shen Fu, Qing Zhang, Xiaomeng Zhang, Xin Cai, Jin Meng, Jingfang Zhao, Yinxiangzi Sheng, Kambiz Shahnazi, Michael F. Moyer; Shanghai Proton and Heavy Ion Center/Fudan University Shanghai Cancer Center; Shanghai Proton and Heavy Ion Center; Shanghai Jiao Tong University Affiliated Sixth People’s Hospital

PURPOSE: To evaluate the toxicities and efficacy of carbon ion therapy for patients with prostate cancer.

MATERIALS AND METHODS: A total of 19 patients with pathologically confirmed prostate cancer were treated with carbon ion therapy from June 2014 to September 2014; 2 had low-risk, 10 had intermediate-risk, and 7 had high-risk prostate cancer. The patients with intermediate-/high-risk disease received neoadjuvant hormone therapy for 2–3 months, followed by concurrent hormone and carbon ion irradiation (63–66 GyE/23–24 Fx with one fraction per day, 5 days per week). The target area included the prostate and partial seminal vesicle, depending on the prognostic risk. Cone-down strategy was adapted in order to avoid the toxicities of the bladder and rectum. Peripheral blood was withdrawn before, during, and after carbon ion therapy.

RESULTS: Immediate outcome: Prostate-specific antigen (PSA) was used to evaluate the response to carbon ion therapy: 7 of 19 (37%) patients had biochemical control (PSA < 0.1 ng/mL) just after the conclusion of carbon ion therapy, and PSA values will be used to determine efficacy of the treatment 3 months after treatment. Also, 7 of 19 patients were diagnosed with abnormal 11 choline–positron emission tomography-computed tomography (PET-CT) before carbon ion therapy. Therefore, 11 choline–PET-CT will be conducted for those patients 3 months after treatment, and the data will be available at the time of the ARS meeting. A total of 7 of 19 patients had statistically higher apparent diffusion coefficient (ADC) values detected by diffusion-weighted imaging (DWI) before radiotherapy than after treatment (P = .0049). Circulating tumor cells (CTCs) in peripheral blood samples could be detected in 7 of 19 patients before carbon ion therapy, but there were no CTCs in 6 of these 7 patients after treatment.

A total of 6 of 19 (32%) patients had variable acute toxicities per the Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03): hematologic system (5), genitourinary (GU) (4), and gastrointestinal (GI) (1). Most toxicities were grade 1; two patients had grade 2 hematologic toxicities. There were no significant differences in specific immunity (T cells: CD3, CD4, CD8 for cellular immunity; B cells: CD19 for humoral immunity) or nonspecific immunity (NK cells: CD16, CD56) before and after carbon ion therapy.

CONCLUSION: This is the first report about a Chinese population with prostate cancer treated with carbon ion therapy. Our primary data showed that carbon ion therapy was well tolerated, and the immediate effect was encouraging. Long-term follow-up is needed for the analysis of final treatment responses and toxicities.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content